MDxHealth (MDXH) Cash & Equivalents (2020 - 2026)

MDxHealth has disclosed Cash & Equivalents across 7 years of filings, most recently posting $43.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $43.2 million, down 34.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.2 million (down 34.29% YoY), and the FY2025 annual result was $46.8 million, up 109.11% from the prior year.
• Cash & Equivalents came in at $43.2 million for Q1 2026 at MDxHealth, up from $29.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $262.0 billion in Q2 2025 to a low of $14.5 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $39.5 million (2023), against an average of $15.4 billion.
• Across the five-year window, Cash & Equivalents slumped 73.5% in 2022 and surged 1227223.84% in 2025, its largest moves.
• MDxHealth's Cash & Equivalents stood at $15.5 million in 2022, then jumped by 44.36% to $22.4 million in 2023, then jumped by 109.11% to $46.8 million in 2024, then sank by 37.96% to $29.0 million in 2025, then soared by 48.64% to $43.2 million in 2026.
• The last three Cash & Equivalents figures came in at $43.2 million (Q1 2026), $29.0 million (Q4 2025), and $46.8 million (Q3 2025), per Business Quant data.